Drugs and toxins associated with myopathies

Current Opinion in Rheumatology

Volumn 10, Issue 6, 1998, Pages 511-520

  Pascuzzi, Robert M ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMINOCAPROIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMIODARONE; ANTILIPEMIC AGENT; BOTULINUM ANTISERUM; BOTULINUM TOXIN; CHLOROQUINE; CLOFIBRATE; COLCHICINE; CORTICOSTEROID; DIDANOSINE; EMETINE; ETRETINATE; GERMANIUM; IODINATED CONTRAST MEDIUM; MAGNESIUM; MEVINOLIN; MUSCLE ENZYME; PENICILLAMINE; PHENYTOIN; PRAVASTATIN; PROCAINAMIDE; QUINIDINE; QUININE; STREPTOKINASE; VECURONIUM DERIVATIVE; ZIDOVUDINE;

ALCOHOL ABUSE; AUTOIMMUNE DISEASE; BOTULISM; COMORBIDITY; DRUG COMBINATION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; MALARIA; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOPATHY; NEUROMUSCULAR DISEASE; PARALYSIS; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TOXICITY; WILSON DISEASE;

BOTULINUM TOXINS; BOTULISM; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE; MUSCULAR DISEASES; MYASTHENIA GRAVIS; NEUROMUSCULAR BLOCKING AGENTS; TOXINS, BIOLOGICAL;

EID: 0031768697     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199811000-00003     Document Type: Review

References (64)

1. Bucknall RC, Dixon A St J, Glick EN, Woodland J, Zutshi DW: Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J 1975, 1:600-602.
2. Czlonkowska A: Myasthenia syndrome during penicillamine treatment. Br Med J 1975, 2:726-727.
3. Russell AS, Lindstrom JM: Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor. Neurology 1978, 28:847-849.
4. Cooperative Systematic Studies of Rheumatic Disease Group: Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis. J Rheumatol 1987, 14:6-73.
5. Andonopoulos AP, Terzis E, Tsibri E, Papasteriades CA, Papetropoulos T: D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence? Clin Rheumatol 1994, 13:586-588.
6. Drosos AA, Christou L, Galanopoulou V, Tzioufas AG, Tsiakou EK: D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings. Clin Exp Rheumatol 1993, 1:387-391.
7. Bruggemann W, Herath H, Ferbert A: Follow-up and immunologic findings in drug-induced myasthenia. Med Klin 1996, 91:268-271.
8. Bever CT Jr, Chang HW, Penn AS, Jaffe IA, Bock E: Penicillamine-induced myasthenia gravis: effects of penicillamine on acetylcholine receptor. Neurology 1982, 32:1077-1082.
9. Seideman P, Ayesh R: Reduced sulphoxidation capacity in D-penicillamine induced myasthenia gravis. Clin Rheumatol 1994, 13:435-437.
10. Perez A, Perella M, Pastor E, Cano M, Escudero J: Myasthenia gravis induced by alfa-interferon therapy. Am J Hematol 1995, 49:365-366.
11. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P: Myasthenia gravis during interferon alfa therapy. Neurology 1995, 45:382-383.
12. Lensch E, Faust J, Nix WA, Wandel E: Myasthenia gravis after interferon alfa treatment. Muscle Nerve 1996, 19:927-928.
13. Piccolo G, Franciotta D, Versino M, Alfonsi E, Lombardi M, Poma G: Myasthenia gravis in a patient with chronic active hepatitis C during interferon-a treatment. Letters to the Editor. J Neurol, Neurosurg, and Psychiatry 1996, 60:348.
14. Mase G, Zorzon M, Biasutti E, Vitrani B, Cazzato G, Urban F, Frezza M: Development of myasthenia gravis during interferon a treatment for anti-HCV positive chronic hepatitis. Journal of Neurol, Neurosurg and Psych 1996, 60:348-349.
15. Konishi T: A case of myasthenia gravis which developed myasthenic crisis after alfa-interferon therapy for chronic hepatitis C. Rinsho Shinkeigaku 1996, 36:980-985.
16. Gu D, Wogensen L, Calcutt N, Xia C, Zhu S, Merlie JP, et al.: Myasthenia gravis-like syndrome induced by expression of interferon in the neuromuscular junction. J Exp Med 1995, 181:547-557.
17. Smith CI, Aarli JA, Biberfeld P, Bolme P, Christensson B, Gahrton G, et al.: Myasthenia gravis after bone marrow transplantation: evidence for a donor origin. N Engl J Med 1983, 309:1565-1568.
18. Bolger GB, Sullivan KM, Spence AM, Appelbaum FR, Johnston R, Sanders JE, et al.: Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. Neurology 1986, 36:1087-1091.
19. Nelson KR, McQuillen MP: Neurologic complications of graft-versus-host-disease. Neurol Clin 1988, 6:389-403.
20. Hayashi M, Matsuda O, Ishida Y, Kida K: Change of immunological parameters in the clinical course of a myasthenia gravis patient with chronic graft-versus-host disease. Acta Paedriatr Jpn 1996, 38:151-155.
21. Grau JM, Casademont J, Monforte R, Marin P, Granena A, Rozman C, Urbano-Marquez A: Myasthenia gravis after allogeneic bone marrow transplantation: report of a new case and pathogenetic considerations. Bone Marrow Transplant 1990, 5:435-437.
22. Zaja F, Russo D, Silvestri F, Barrillari G, Fanin R, Cerno M, et al.: Myasthenia gravis after allogeneic bone marrow transplantation: a case report. Bone Marrow Transplant 1995, 15:649-653.
23. Adams C, August CS, Maguire H, Sladky JT: Neuromuscular complications of bone marrow transplantation. Pediatr Neurol 1995, 12:58-61.
24. Krendel DA: Hypermagnesemia and neuromuscular transmission. Semin Neurol 1990, 10:42-45.
25. Cherington M: The clinical spectrum of botulism. Muscle Nerve 1998, 21:701-710. This is a sterling landmark review on botulism.
26. Montecucco C, Schiavo G, Tugnoli V, de Grandis D: Botulinum neurotoxins: mechanism of action and therapeutic applications. Mol Med Today 1996, 10:418-424.
27. Olney RK, Aminoff MJ, Gelb DJ, Lowentein DH: Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988, 38:1780-1783.
28. Holzer SE, Ludlow CL: The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia. Laryngoscope 1996, 106:86-92.
29. Comella CL, Tanner CM, DeFoor-Hill L, Smith C: Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiographic findings. Neurology 1992, 42:1307-1310.
30. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C: Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. Journal of Neurol Neurosurg and Psychiatry 1992, 55:844-845.
31. Watling SM, Dasta JF: Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994, 22:884-893.
32. Hund EF: Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure. Journal of the Neurological Sciences 1996, 136:10-16.
33. Maher J, Rutledge F, Remtulla H, Parkes A, Bernardi L, Bolton CF: Neuromuscular disorders associated with failure to wean from the ventilator. Intensive Care Med 1995, 21:737-743.
34. Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, Libby NP, et al: Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992, 42:2082-2087.
35. Lacomis D, Smith TW, Chad DA: Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve 1993, 16:84-90.
36. Zochodne DW, Ramsay DA, Saly V, Shelley S, Moffatt S: Acute necrotizing myopathy of intesnsive care: electrophysiologic studies. Muscle Nerve 1994, 17:285-292.
37. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ: Acute myopathy of intensive care: clinical, electromyographic and pathological aspects. Ann Neurol 1996, 40:645-654.
38. Rich MM, Teener JW, Raps EC, Schotland MD, Bird SJ, et al: Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996, 46:731-736.
39. Al-Lozi MT, Pestronk A, Yee WC, Flaris N, Cooper J: Rapidly evolving myopathy with myosin-deficiency muscle fibers. Ann Neurol 1994, 35:273-279.
40. Sandrock AW, Cros D, Louis DN: Weekly clinicopathological exercises. Case Records of the Massachusetts General Hospital. N Engl J Med 1997, 336:1079-1088. Superb case presentation and discussion of the differential diagnosis of acute weakness in the ICU patient.
41. Faragher MW, Day BJ, Dennett X: Critical care myopathy: an electrophysiological and histological study. Muscle Nerve 1996, 19:516-518.
42. Showalter CJ, Engel AG: Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997, 20:316-322. New insight regarding the pathogenesis of acute quadriplegic myopathy.
43. Hanson P, Dive A, Brucher JM, Bisteau M, Dangoisse M, Deltombe T: Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20:1371-1380. Corticosteroids without neuromuscular blockers can cause acute severe myopathy.
44. Latronico N: Acute myopathy of intensive care. Ann Neuro 1997, 42:131-132.
45. Robberecht W, Bodnarik J, Bourgeois P, van Hees J, Carton H: Myasthenic syndrome caused by a direct effect of chloroquine on neuromuscular transmission. Arch Neurol 1989, 46:464-468.
46. De Bleecker J, De Reuck J, Quatacker J, et al: Persistent chloroquine-induced myasthenia. Acta Clin Belg 1991, 46:401-406.
47. Sghirlanzoni A, Mantegazza R, Mora M, Pareyson D, Cornelio F: Chloroquine myopathy and myasthenia-like syndrome. Muscle & Nerve 1988, 11:114-119.
48. Canal N, Franceschi M: Myasthenic crisis precipitated by iothalamic acid. Lancet 1983, 1:1288.
49. Chagnac Y, Hadani M, Goldhammer Y: Myasthenic crisis after intravenous administration of iodinated contrast agent. Neurology 1985, 35:1219-1220.
50. Vanden Bergh P, Kelly JJ, Carter B, Munsat TL: Intravascular contrast media and neuromuscular junction disorders. Arch Neurol 1986, 19:206-207.
51. Eliashiv S, Wirguin I, Brenner T, Argov Z: Aggravation of human and experimental myasthenia gravis by contrast media. Neurology 1990, 49:1623-1625.
52. Frank JH, Cooper GW, Black WC, Phillips LH: Iodinated contrast agents in myasthenia gravis. Neurology 1987, 37:1400-1402.
53. Dropcho EJ, Soong SJ: Steroid-induced weakness in patients with primary brain tumors. Neurology 1991, 41:1235-1239.
54. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM: Steroid myopathy in cancer patients. Neurology 1997, 48:1234-1238. prospective study documenting 60% of steroid treated patients developed myopathy.
55. Bowyer SL, LaMothe MP, Hollister JR: Steroid myopathy: incidence and detection in a population with Asthma. J Allergy Clin Immunol 1985, 76:234-242.
56. Marshall LF, King J, Langfitt TW: The complications of high dose corticosteroid therapy in neurosurgical patients: a prospective study. Ann Neurol 1977, 1:201-203.
57. Di Muzio A, Di Guglielmo G, Feliciani C, DeLuca G, DiMuzio M, Uncini A: Inflammatory myopathy after intravenous streptokinase. Muscle Nerve 1997, 20:619-621. First report of streptokinase induced inflammatory myopathy.
58. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
59. Norman DJ, Illingworth DR, Munson J, Hosenpud J: Myolysis and acute renal failture in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988, 318:46-47.
60. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C: Polymyositis associated with simvastatin. The Lancet 1997, 349:1600-1601. Inflammatory myopathy in associating with simvastatin.
61. Lange DJ: Neuromuscular diseases assoicated with HIV-1 infection. Muscle Nerve 1994, 17:16-30.
62. Simpson DM, Slasor P, Dafni U, Berger J, Fischl MA, Hall C: Analysis of myopathy in a placebo-controlled zidovudine trial. Muscle Nerve 1997, 20:382-385. Myalgias and increased CK are frequent and not generally associated with clinical weakness.
63. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098-1105.
64. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, et al.: Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991, 29:606-614.